The Influence of Thromboxane Receptor Blockade on Platelet Uptake in Dacron Grafts in Man
Human prosthetic vascular grafts do not sustain a growth of endothelium on the luminal surface and remain thrombogenic indefinitely1. Whilst large diameter aortic grafts develop a thin layer of platelet thrombus as pseudointima, smaller prostheses such as those in the femoro-popliteal position have a thrombosis and occlusion rate approaching 60% at 1 year after implantation2. Platelet inhibitory therapy is established in the prevention of thrombosis but the combination of aspirin plus dipyridamole produces frequent gastro-intestinal side effects. This has been shown in the recent Persantin Aspirin Re-infarction Study3 where 25% of patients had to discontinue aspirin therapy. Thromboxane A2 (TXA2) which is a product of aracidonic acid metabolism, is a powerful stimulator of platelet aggregation4. It is produced by enzymes including cyclo-oxygenase and thromboxane synthetase in platelets and the natural biological opponent of TXA2 is prostocyclin (PGI2).
KeywordsDacron Graft Platelet Thrombus Platelet Survival Thromboxane Synthetase Charing Cross Hospital
Unable to display preview. Download preview PDF.
- 1.M. Goldman, H.C. Norcott, R.J. Hawker, Z. Drolc and C.N. McCollum, Platelet accumulation on mature Dacron grafts in man, Br. J. Surg. 69 (Suppl.): 538, (1982).Google Scholar
- 3.Paris Research group, Persantin and aspirin in coronary heart disease, Circulation, 62: 449, (1980).Google Scholar
- 7.D.J. Doyle, C.N. Chesterman, J.F. Casle and F.J. Morgan, Platelet concentrations of platelet specific proteins correlated with platelet survival, Thromb. and Haemost. 42: 329 (1979).Google Scholar
- 9.M. Goldman, C. Hall, R.J. Hawker and C.N. McCollum, Dazoxiben 147 examined for platelet inhibitory effect in an artificial circulation, Br. J. Pharmac. 15:615 (1983).Google Scholar